Nuvalent, Inc. financial data

Symbol
NUVL on Nasdaq
Industry
Pharmaceutical Preparations
Location
One Broadway, 14 Th Floor, Cambridge, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.9K % -17.6%
Debt-to-equity 5.5 % +22.5%
Return On Equity -28.8 % -12.6%
Return On Assets -27.3 % -11.6%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 1.1B USD +360%
Weighted Average Number of Shares Outstanding, Basic 64.6M shares +13.6%
Weighted Average Number of Shares Outstanding, Diluted 64.6M shares +13.6%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 153M USD +78.9%
General and Administrative Expense 50M USD +75.7%
Operating Income (Loss) -203M USD -78.1%
Nonoperating Income (Expense) 29.9M USD +116%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -57M USD -95.9%
Income Tax Expense (Benefit) 170K USD
Net Income (Loss) Attributable to Parent -174M USD -73.4%
Earnings Per Share, Basic -2.79 USD/shares -50%
Earnings Per Share, Diluted -2.79 USD/shares -50%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 77.7M USD +9.63%
Marketable Securities, Current 580M USD +61%
Assets, Current 666M USD +52.5%
Other Assets, Noncurrent 8.97M USD +81%
Assets 675M USD +52.8%
Accounts Payable, Current 7.4M USD -8.8%
Employee-related Liabilities, Current 4.91M USD +57.6%
Accrued Liabilities, Current 30.8M USD +143%
Liabilities, Current 38.2M USD +83.7%
Liabilities 38.2M USD +83.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.57M USD -2.21%
Retained Earnings (Accumulated Deficit) -388M USD -81%
Stockholders' Equity Attributable to Parent 637M USD +51.3%
Liabilities and Equity 675M USD +52.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -36.1M USD -47.8%
Net Cash Provided by (Used in) Financing Activities 5.99M USD
Net Cash Provided by (Used in) Investing Activities -207M USD -62.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -237M USD -56.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 77.7M USD +9.63%
Deferred Tax Assets, Valuation Allowance 101M USD +93.6%
Cash and Cash Equivalents, Period Increase (Decrease) -1.25M USD -131%
Deferred Tax Assets, Gross 101M USD +93.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -174M USD -72.7%
Deferred Tax Assets, Operating Loss Carryforwards 35.1M USD +41.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 5K USD +25%
Share-based Payment Arrangement, Expense 43.3M USD +157%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%